Invega Trinza (paliperidone palmitate)
Invega Trinza (paliperidone palmitate, 3‑month injection)
Brand name: Invega® Trinza®
Active ingredient: Paliperidone palmitate
Type: Atypical antipsychotic
Available from: Janssen Inc.
Form: Long‑acting injection (every 3 months)
Generic: No
Listed on Ontario formulary: Yes (with suggested criteria*)
OHIP+ coverage: Yes (with suggested criteria*)
*Criteria include established tolerance and clinical benefit on Invega Sustenna for at least 4 months.
What is Invega Trinza used for?
Treatment of schizophrenia and related psychotic illnesses in adults.
Approved by Health Canada in 2016.
How should I take Invega Trinza?
Administered every 3 months by a healthcare provider.
Available in 175 mg, 263 mg, 350 mg, 525 mg prefilled syringes.
Must be stable on Invega Sustenna before transitioning.
Common side effects
Same as Sustenna:
- Headache
- Insomnia
- Constipation
- Nausea/vomiting
- Injection‑site pain
- Weight gain
- Restlessness
- Dizziness
- Abnormal movements
Rare but serious side effects
Same as other paliperidone products.
Warnings/Precautions
Same dementia‑related mortality warning as other antipsychotics.
Medication interactions
Same as oral Invega and Sustenna.